BR112022020973A2 - Composições farmacêuticas e produtos farmacêuticos de interleucina-15 humana heterodimérica (hetil-15) - Google Patents
Composições farmacêuticas e produtos farmacêuticos de interleucina-15 humana heterodimérica (hetil-15)Info
- Publication number
- BR112022020973A2 BR112022020973A2 BR112022020973A BR112022020973A BR112022020973A2 BR 112022020973 A2 BR112022020973 A2 BR 112022020973A2 BR 112022020973 A BR112022020973 A BR 112022020973A BR 112022020973 A BR112022020973 A BR 112022020973A BR 112022020973 A2 BR112022020973 A2 BR 112022020973A2
- Authority
- BR
- Brazil
- Prior art keywords
- hetyl
- pharmaceutical compositions
- pharmaceutical
- compositions
- human heterodimeric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013801P | 2020-04-22 | 2020-04-22 | |
| PCT/IB2021/053254 WO2021214658A1 (en) | 2020-04-22 | 2021-04-20 | Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetil-15) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020973A2 true BR112022020973A2 (pt) | 2022-12-06 |
Family
ID=75639945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020973A BR112022020973A2 (pt) | 2020-04-22 | 2021-04-20 | Composições farmacêuticas e produtos farmacêuticos de interleucina-15 humana heterodimérica (hetil-15) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210330747A1 (OSRAM) |
| EP (1) | EP4138782A1 (OSRAM) |
| JP (1) | JP2023523218A (OSRAM) |
| KR (1) | KR20230004655A (OSRAM) |
| CN (1) | CN115443127A (OSRAM) |
| AR (1) | AR122428A1 (OSRAM) |
| AU (1) | AU2021260989A1 (OSRAM) |
| BR (1) | BR112022020973A2 (OSRAM) |
| CA (1) | CA3178895A1 (OSRAM) |
| CO (1) | CO2022014867A2 (OSRAM) |
| IL (1) | IL297326A (OSRAM) |
| MX (1) | MX2022013352A (OSRAM) |
| TW (1) | TW202214290A (OSRAM) |
| WO (1) | WO2021214658A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7083206B2 (ja) | 2019-06-28 | 2022-06-10 | 国立大学法人 東京大学 | タンパク質内包高分子ミセル |
| EP4434998A4 (en) * | 2021-11-18 | 2025-06-18 | Shandong Simcere Biopharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION OF IL-15 MUTANT FUSION PROTEIN |
| KR20250144433A (ko) * | 2023-02-14 | 2025-10-10 | 아크론 바이오프로덕츠 엘엘씨 | 생체내 이용을 위한 인터루킨 제형물 |
| CN117883565A (zh) * | 2023-12-25 | 2024-04-16 | 中山大学 | 沙美特罗和pd-1抗体联用在制备治疗黑色素瘤的药物中的应用 |
| WO2025206413A1 (en) * | 2024-03-28 | 2025-10-02 | The University Of Tokyo | Protein-enclosing polymeric complexes |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| PL1899364T5 (pl) | 2005-05-17 | 2024-12-09 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| EP1984505B1 (en) | 2006-01-13 | 2019-12-25 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells |
| DK2160401T3 (da) | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| EP2249809A1 (en) * | 2008-01-15 | 2010-11-17 | Abbott GmbH & Co. KG | Powdered protein compositions and methods of making same |
| CN102099221B (zh) | 2008-08-22 | 2014-01-29 | 麦格纳座椅公司 | 具有减小空转的盘形调角器 |
| KR101746881B1 (ko) * | 2009-10-21 | 2017-06-14 | 오웬 멈포드 리미티드 | 오토인젝터 |
| EP2619229B1 (en) | 2010-09-21 | 2016-04-06 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| BR122021025267B1 (pt) * | 2013-02-22 | 2023-12-05 | Curevac Ag | Partes de kit e composição farmacêutica compreendendo um inibidor da via de pd-1 |
| WO2016018920A1 (en) * | 2014-07-29 | 2016-02-04 | Admune Therapeutics Llc | Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions |
| WO2017177063A1 (en) * | 2016-04-06 | 2017-10-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of heterodimeric il-15 in adoptive cell transfer |
| PL3639845T3 (pl) * | 2017-07-25 | 2023-10-23 | Jiangsu Hengrui Medicine Co., Ltd. | Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania |
| CA3102821A1 (en) * | 2018-06-22 | 2019-12-26 | Cugene Inc. | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
| KR20220005028A (ko) * | 2019-04-26 | 2022-01-12 | 루비우스 테라퓨틱스, 아이엔씨. | 탈핵 적혈구를 포함하는 조성물 |
-
2021
- 2021-04-20 IL IL297326A patent/IL297326A/en unknown
- 2021-04-20 US US17/234,914 patent/US20210330747A1/en active Pending
- 2021-04-20 KR KR1020227040050A patent/KR20230004655A/ko active Pending
- 2021-04-20 BR BR112022020973A patent/BR112022020973A2/pt unknown
- 2021-04-20 EP EP21720852.9A patent/EP4138782A1/en active Pending
- 2021-04-20 CN CN202180030326.7A patent/CN115443127A/zh active Pending
- 2021-04-20 JP JP2022563971A patent/JP2023523218A/ja active Pending
- 2021-04-20 WO PCT/IB2021/053254 patent/WO2021214658A1/en not_active Ceased
- 2021-04-20 TW TW110114219A patent/TW202214290A/zh unknown
- 2021-04-20 AU AU2021260989A patent/AU2021260989A1/en active Pending
- 2021-04-20 MX MX2022013352A patent/MX2022013352A/es unknown
- 2021-04-20 CA CA3178895A patent/CA3178895A1/en active Pending
- 2021-04-22 AR ARP210101082A patent/AR122428A1/es unknown
-
2022
- 2022-10-19 CO CONC2022/0014867A patent/CO2022014867A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL297326A (en) | 2022-12-01 |
| AR122428A1 (es) | 2022-09-07 |
| CN115443127A (zh) | 2022-12-06 |
| MX2022013352A (es) | 2022-11-30 |
| CA3178895A1 (en) | 2021-10-28 |
| CO2022014867A2 (es) | 2022-10-31 |
| AU2021260989A1 (en) | 2022-11-17 |
| JP2023523218A (ja) | 2023-06-02 |
| US20210330747A1 (en) | 2021-10-28 |
| WO2021214658A1 (en) | 2021-10-28 |
| EP4138782A1 (en) | 2023-03-01 |
| TW202214290A (zh) | 2022-04-16 |
| KR20230004655A (ko) | 2023-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022014867A2 (es) | Composiciones farmacéuticas y productos farmacéuticos de interleucina–15 humana heterodimérica (hetil–15) | |
| MX2024007633A (es) | Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas. | |
| CL2018002920A1 (es) | Nuevos derivados de pirazolopirimidina | |
| CL2019002255A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas. | |
| BR112019008458A2 (pt) | 1,2,4-triazolonas 2,4,5-trisubstituídas. | |
| ECSP20008441A (es) | Dihidrooxadiazinonas | |
| CO2022007005A2 (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune | |
| PH12019501824A1 (en) | Anti-gprc5d antibody and molecule comprising the antibody | |
| JOP20170135A1 (ar) | مركبات ديازاسبيروألكيل مثيل-إندول | |
| DOP2020000023A (es) | Nuevos derivados de quinolina | |
| BR112022002442A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| UY37460A (es) | 1,2,4-triazolonas con anelación en 4 y 5 | |
| CU23923B1 (es) | Polipéptidos derivados de la il-2 con actividad agonista | |
| BR112023006024A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| UY37577A (es) | Dihidroimidazopiridindionas sustituidas | |
| BR112022004397A2 (pt) | Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos | |
| BR112022003932A2 (pt) | Composições para tratamento bucal que compreendem beta ácidos de lúpulo e fluoreto | |
| PH12020551994A1 (en) | Tlr7 agonists | |
| BR112023004860A2 (pt) | Construto de interleucina 15 (il15), composição farmacêutica, método de tratamento de câncer e método para aumentar a sobrevivência de uma célula imune | |
| BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
| MX2020005310A (es) | Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo. | |
| JOP20220313A1 (ar) | تركيبة دوائية مائية من الليفيليماب وإستخدامها | |
| BR112018070064A2 (pt) | composições farmacêuticas estáveis para administração tópica e uso das mesmas | |
| CO2021016879A2 (es) | Formulaciones estabilizadas de ditiocarbamatos | |
| PL431336A1 (pl) | Lipopeptydy, kompozycja farmaceutyczna, kompozycja kosmetyczna oraz lipopeptydy do zastosowania jako lek |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025026726-0 PROTOCOLO 870250111105 EM 03/12/2025 17:03. |